Recce Pharmaceuticals accelerates R327 trial for UTI patients with faster infusion rate approval
Recce Pharmaceuticals Ltd (ASX:RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.
© 2025 Recce Pharmaceuticals